Correlation of PIM kinases with tumor immune microenvironment and clinical presentation of metastatic hormone-sensitive prostate cancer.

被引：0
|
作者：
Recio-Boiles, Alejandro
Clements, Amber N.
Deshmukh, Sachin Kumar
Bertolo, Aaron
Estrada-Mendizabal, Ricardo J.
Saboda, Kathylynn
Wu, Sharon
Xiu, Joanne
Radovich, Milan
Sutterby, Kai
Chauhan, Shailender S.
McKay, Rana R.
Nabhan, Chadi
Warfel, Noel A.
机构：
[1] Univ Arizona, Canc Ctr, Tucson, AZ USA
[2] Caris Life Sci, Phoenix, AZ USA
[3] Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey, Mexico
[4] Univ Calif San Diego, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [21] Approval for Zytiga® in metastatic hormone-sensitive Prostate Cancer
    Junker, Annette
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
  • [22] Modern treatment of metastatic hormone-sensitive prostate cancer
    Kuronya Zsofia
    Biro Krisztina
    Geczi Lajos
    Maraz Aniko
    ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
  • [23] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
    Sweeney, Christopher J.
    Chen, Yu-Hui
    Carducci, Michael
    Liu, Glenn
    Jarrard, David F.
    Eisenberger, Mario
    Wong, Yu-Ning
    Hahn, Noah
    Kohli, Manish
    Cooney, Matthew M.
    Dreicer, Robert
    Vogelzang, Nicholas J.
    Picus, Joel
    Shevrin, Daniel
    Hussain, Maha
    Garcia, Jorge A.
    DiPaola, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 737 - 746
  • [24] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Arnold Lee
    Targeted Oncology, 2023, 18 : 793 - 800
  • [25] Optimal treatment for metastatic hormone-sensitive prostate cancer
    Omlin, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
  • [26] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Lee, Arnold
    TARGETED ONCOLOGY, 2023, 18 (05) : 793 - 800
  • [27] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
    Li, Hengping
    Zhang, Mao
    Wang, Xiangrong
    Liu, Yang
    Li, Xuanpeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Drug therapy of hormone-sensitive metastatic prostate cancer. Consensus paper of the AKO/AUO
    Ohlmann, C-H.
    Gschwend, J.
    Miller, K.
    UROLOGE, 2016, 55 (09): : 1164 - 1172
  • [29] Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply
    Borque-Fernando, A.
    Calleja-Hernandez, M. A.
    Cozar-Olmo, J. M.
    Gomez-Iturriaga, A.
    Perez-Fentes, D. A.
    Puente-Vazquez, J.
    Rodrigo-Aliaga, M.
    Unda, M.
    Alvarez-Ossorio, J. L.
    ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (06): : 392 - 393
  • [30] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Montesa-Pino, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe
    Tammela, Teuvo L. J.
    Suzuki, Hiroyoshi
    Utriainen, Tapio
    Fu, Cheng
    Uemura, Motohide
    Mendez-Vidal, Maria J.
    Maughan, Benjamin L.
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142
12345